The HDSA recently coordinated a meeting between Huntington’s disease families and the US regulatory agency that approves medicines, to amplify the community’s voice and help move us toward treatments.
Changes in thinking, learning, and memory are some of the most distressing and impactful in Huntington’s disease. Sage Therapeutics was advancing their drug dalzanemdor to treat these symptoms, but unfortunately this program will be halted.
Scientists have found more people have the genetic changes that underlie repeat expansion diseases, like HD, than previously thought. This new data tells doctors to consider expansion diseases more when diagnosing people with neurological symptoms.
Read updates from clinical trials and scientific research on Huntington’s disease from Day 3 of the 2024 Huntington Study Group conference.
Read updates from clinical trials and scientific research on Huntington’s disease from Day 1 of the 2024 Huntington Study Group conference #HSG2024
Read updates from clinical trials and scientific research on Huntington’s disease from Day 2 of the 2024 Huntington Study Group conference
We're proud to announce Molly Gracey as a 2024 HDBuzz Prize winner! Could social skills be the secret ingredient to a better quality of life in people with #HuntingtonsDisease? Clues suggest these 'hidden gems' impact #QualityOfLife in HD.
We're proud to announce Dr. Zanna Voysey as a 2024 HDBuzz Prize winner! She shares a new study that details racial disparities in HD care and research. Addressing this could improve the lives of people living with HD in the here-and-now.
The 2024 #HDBuzz Prize for Young #Science Writers opened this summer. We’ll bring you #HuntingtonsDisease #research articles from the winners through the next few months, sharing fresh voices on HDBuzz. (Trophy not included.)
Moving drugs from the lab bench to pharmacy shelves is no small task. In this article we delve into the role regulatory oversight plays in clinical trials and the approval of medicines for Huntington’s disease.
A CRISPR-based approach called “base editing” is being explored to develop a new potential treatment for Huntington's disease. Editing a single letter in the genetic code with base editing may be the key for delaying HD symptoms, maybe by a decade.